Guideline position, pivotal evidence, effect sizes, negative findings — stress urinary incontinence

1. Summary

The domain dossier already establishes that the AUA/SUFU guideline places pelvic floor muscle training (PFMT) at Expert Opinion grade rather than a stronger recommendation, and that a Cochrane review found non-implanted electrical stimulation (ES) probably better than no treatment but not clearly better than PFMT itself. This report adds five findings not previously on record for the domain: quantified effect sizes for weighted vaginal cones and for commercially available home pelvic-training devices as a device class, a meta-regression identifying which biofeedback-assisted PFMT parameters predict better cure rates, a sham-controlled trial that is the closest available test of the feedback-gated mechanism this domain's device candidates rely on, and two recent network meta-analyses that rank conservative SUI treatments against one another. Two independently constructed network meta-analyses — one specific to stress urinary incontinence (31 RCTs, n=1,900) and one a 2025 Cochrane review in women aged 60 and over (43 RCTs, n=8,506) — both rank device-augmented conservative therapy (electrical stimulation, or biofeedback combined with electrical stimulation) at or above PFMT alone on their own primary ranking metric, though neither grades the underlying evidence above low-to-very-low certainty, and the two reviews do not agree on which single modality ranks highest. No trial of a closed-loop, EMG-gated stimulation device specifically was located; the closest substitute, a small sham-controlled EMG-biofeedback trial, found the sham-feedback arm improved as much as the active-feedback arm — a negative finding for the value of the feedback signal itself, detailed in section 3.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Network meta-analyses — how conservative modalities rank against each other

A 2024 network meta-analysis of RCTs measuring conservative SUI treatments directly against one another (rather than each against a separate control) included "31 RCTs involving 1,900 patients across 8 intervention categories" and ranked them by SUCRA (surface under the cumulative ranking curve) on two outcomes. For the ICIQ-UI SF symptom score, "electrical stimulation (SUCRA = 95.9%) was the most effective therapy," followed by "biofeedback electrical stimulation (SUCRA = 84.9%)," with "pelvic floor muscle training (SUCRA = 38.4%)" ranked sixth of eight. For reducing urine leakage on the same trial set, the ranking order changed: "Er:YAG laser (SUCRA = 97.5%), biofeedback electrical stimulation (SUCRA = 83.4%)... electrical stimulation (SUCRA = 48.4%), pelvic floor muscle training (SUCRA = 43.0%)." The review's own conclusion, combining both metrics, states "biofeedback electrical stimulation may be the optimal therapy for the conservative management of stress urinary incontinence" [single-source] [1].

A 2025 Cochrane network meta-analysis of urinary incontinence treatment in women 60 and older — a broader population than SUI alone, since it did not restrict to stress-type incontinence — included "43 RCTs involving 8506 participants" and found "physical therapies," predominantly PFMT with or without adjuncts, ranked best for "cure": "physical therapies combined with complementary therapies (odds ratio (OR) 17.79, 95% confidence interval (CI) 2.97 to 106.46; 1 study, 71 participants)... physical therapies (OR 7.20, 95% CI 2.59 to 20.03; 4 studies, 310 participants)," each rated "very low-certainty evidence." Its own authors conclude "the number and quality of studies were insufficient to draw firm conclusions about the most effective treatment for urinary incontinence in older women" [single-source] [2]. Read together, [1] and [2] agree that some form of device-augmented conservative therapy outranks PFMT alone on at least one ranking metric each, but they disagree on which single modality that is — [1] favors electrical stimulation or biofeedback-plus-stimulation for a SUI-specific population, while [2] favors PFMT-based physical therapy (not electrical stimulation) for cure in an older, broader-incontinence population — and both caution that SUCRA/OR rankings from indirect, heterogeneous trial networks are not head-to-head evidence.

Guideline position — what is graded, and what is not

The current AUA/SUFU guideline (2023 amendment) grades pelvic floor muscle exercises "± biofeedback" at Expert Opinion, alongside pessary and vaginal inserts, as a non-surgical option in Guideline Statement 11. The guideline's own evidence-graded statements do not include a separate recommendation for electrical stimulation or weighted vaginal cones as standalone non-surgical treatments — biofeedback appears only as an optional adjunct to PFMT, not as its own graded item. The published guideline is titled around its surgical scope ("Surgical Treatment of Female Stress Urinary Incontinence"), but Statement 11's non-surgical options are part of the same document [single-source] [3].

Weighted vaginal cones — effect sizes and equivalence claims

A Cochrane review of 23 trials (n=1,806 women, 717 on cones, search through March 2013) found "cones were better than no active treatment (rate ratio (RR) for failure to cure incontinence 0.84, 95% CI 0.76 to 0.94)." Against the domain's other two conservative modalities, the review found no clear difference: "little evidence of difference for a subjective cure between cones and PFMT (RR 1.01, 95% CI 0.91 to 1.13), or between cones and electrostimulation (RR 1.26, 95% CI 0.85 to 1.87), but the confidence intervals were wide." The authors' own conclusion is explicitly tentative: cones "may be of similar effectiveness to PFMT and electrostimulation," pending "larger, high-quality trials" [single-source] [4].

Commercially available home pelvic-training devices — device-class effect sizes

A 2022 meta-analysis (26 studies screened qualitatively, 15 meta-analyzed, search through April

1. of commercially available home pelvic muscle training devices — excluding plain vaginal

weights/cones and peripartum-only studies — reported: "a reduction of 1.2 pads per day (P<.01), 1.3 incontinence episodes per day (P<.01) and 11 g on 24-hour pad test (P<.01)... a reduction in UDI-6... scores by 25.1 points (P<.01) and in IIQ-7... scores by 14.1 points (P=.01)... an increase in I-QOL... scores by 16.8 points (P<.01)." The minimal important difference was "met for the UDI-6 and I-QOL but not for the IIQ-7," and the authors state they "were unable to perform meta-analysis to evaluate whether pelvic floor training devices are as effective as traditional supervised pelvic floor physical therapy" [single-source] [5]. The abstract does not name which specific commercial products (e.g. InTone, ELITONE) contributed to the pooled estimate, so this is device-class evidence, not a validation of any one named incumbent.

Biofeedback-assisted PFMT — effect sizes and what predicts a better cure rate

A 2026 systematic review with meta-analysis and meta-regression (21 studies, n=2,373, search through May 2025) found invasive (intravaginal) biofeedback-assisted PFMT improved pelvic floor muscle strength (SMD 0.71, 95% CI 0.29–1.14, p=0.001), symptom severity (SMD -0.33, 95% CI -0.63 to -0.03, p=0.032), quality of life (SMD -1.10, 95% CI -1.78 to -0.41, p=0.002) and improvement/cure rate (OR 2.02, 95% CI 1.25–3.26, p=0.004) versus comparators. Its meta-regression found "higher improvement/cure rates when BF-assisted PFMT involved mildly challenging exercises, tailoring to patients' abilities, therapist supervision, sessions of <10 min, durations of >1 h/week for ≥8 weeks, and ≥80%-95% adherence" — an adherence dependency the authors flag as needing confirmation given "methodological flaws, risks of bias, and substantial heterogeneity" [single-source] [6].

EMG biofeedback versus sham — the closest test of a feedback-gated mechanism

No registered trial of a closed-loop, EMG-gated electrical stimulation device for SUI was located: a direct trials-connector query for condition "stress urinary incontinence" and intervention "closed loop stimulation" returned zero registered records. The closest available substitute is a sham-controlled RCT (NCT05366426, sponsor Kirsehir Ahi Evran Universitesi, an academic sponsor, enrollment 60 women, no results yet posted to the registry itself) whose published results randomized women to PFMT alone, EMG biofeedback, or sham EMG biofeedback, 24 sessions over 8 weeks. The published result: "No significant improvement was found in the control group in all parameters of ICIQ-SF (p>0.05), while significant improvement was found in the EMG-BF and Sham EMG-BF groups (p<0.001 for each)... In the Pad test EMG-BF and Sham EMG-BF groups showed significant improvement compared to the control group (p<0.001)." The paper's own conclusion states "Adding EMG-BF therapy to PFMT exercises is effective," but its own results table does not show the active EMG-BF arm outperforming the sham-feedback arm — both improved over PFMT-alone by a similar margin, on the outcomes the abstract reports [single-source] [7] [sponsor-reported] [8]. Read narrowly, this is one small (n=60), single-center trial and does not establish that feedback signal fidelity is irrelevant to outcome; it is evidence that in this specific trial, a real-time EMG signal added no detectable benefit over a sham signal when both accompanied a structured training session.

Postpartum-specific combined therapy — a narrower population

A 2026 meta-analysis (20 studies, n=2,421, search through October 2024) restricted to postpartum SUI found biofeedback electrical stimulation (BFES) combined with PFMT "significantly improved PSUI clinical effect, pelvic floor muscle strength, and muscle fiber potential, reduced daily urinary incontinence incidence... compared with BFES or PFMT alone," while flagging "high heterogeneity" and "publication bias in the analysis of" incontinence-event counts [single-source] [9]. This population is postpartum women specifically, a subset of the domain's broader adult-women population, and the finding should not be generalized to non-postpartum SUI without a postpartum-specific caveat.

4. Sources

[1] Conservative treatments for women with stress urinary incontinence: a systematic review and network meta-analysis — Frontiers in Medicine (published 2024, month and day not given in the PubMed record; accessed 2026-09-01). PMID 39703522 — https://pubmed.ncbi.nlm.nih.gov/39703522/ [peer-reviewed] [2] Interventions for treating urinary incontinence in older women: a network meta-analysis — Cochrane Database of Systematic Reviews (published 2025-11-27; accessed 2026-09-01). PMID 41307301 — https://pubmed.ncbi.nlm.nih.gov/41307301/ [peer-reviewed] [3] Updates to Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline (2023) — The Journal of Urology, American Urological Association / SUFU (published 2023-06, day not given in the PubMed record; accessed 2026-09-01). PMID 37096580 — https://www.auanet.org/guidelines-and-quality/guidelines/stress-urinary-incontinence-(sui)-guideline [guideline] [4] Weighted vaginal cones for urinary incontinence — Cochrane Database of Systematic Reviews (published 2013-07-08; accessed 2026-09-01). PMID 23836411 — https://pubmed.ncbi.nlm.nih.gov/23836411/ [peer-reviewed] [5] Commercially Available Home Pelvic Training Devices for the Treatment of Pelvic Floor Disorders: A Systematic Review and Meta-analysis — Obstetrics and Gynecology (published 2022-08-01; accessed 2026-09-01). PMID 35852280 — https://pubmed.ncbi.nlm.nih.gov/35852280/ [peer-reviewed] [6] The effectiveness of invasive and non-invasive biofeedback-assisted pelvic floor muscle training with or without electrical stimulation for the treatment of stress urinary incontinence in women: a systematic review with meta-analysis and meta-regression of randomized controlled trials — Therapeutic Advances in Urology (published 2026, month not given precisely in the PubMed record — listed as "Jan-Dec 2026"; accessed 2026-09-01). PMID 41536925 — https://pubmed.ncbi.nlm.nih.gov/41536925/ [peer-reviewed] [7] The Effect of EMG biofeedback in female patients with stress urinary incontinence: a randomized sham controlled blinded clinical study — Irish Journal of Medical Science (published 2026-04-11; accessed 2026-09-01). PMID 41964834 — https://pubmed.ncbi.nlm.nih.gov/41964834/ [peer-reviewed] [8] Effect of EMG Biofeedback in Female Patients With Stress Urinary Incontinence — ClinicalTrials.gov, sponsor Kirsehir Ahi Evran Universitesi (status COMPLETED, hasResults=false; record last updated 2024-12-11; accessed 2026-09-01). NCT05366426 — https://clinicaltrials.gov/study/NCT05366426 [trial-registry] [9] Biofeedback electrical stimulation combined with pelvic floor muscle training on postpartum stress urinary incontinence: A meta-analysis — International Journal of Gynaecology and Obstetrics (published 2026-02, day not given in the PubMed record; accessed 2026-09-01). PMID 40747885 — https://pubmed.ncbi.nlm.nih.gov/40747885/ [peer-reviewed]

5. Sourcing & Gaps

Well established: Only one line in this report rests on ≥2 independent, non-affiliated primary sources: that some form of device-augmented conservative therapy (electrical stimulation, or biofeedback combined with electrical stimulation) outranks PFMT alone on at least one primary ranking metric in each of two differently constructed network meta-analyses [1][2]. Which single modality ranks highest is not agreed between them.

Thin: Every other quantitative finding in section 3 rests on exactly one source and carries [single-source]: the AUA/SUFU guideline's scope [3], the cones review's three effect sizes [4], the commercial-device meta-analysis's six effect sizes [5], the biofeedback meta-regression [6], the EMG-biofeedback-versus-sham result [7], and the postpartum BFES meta-analysis [9]. The EMG-biofeedback trial's registry record [8] carries [sponsor-reported] because it has no results posted to ClinicalTrials.gov itself — the published-paper result [7] is the only place its outcome data was actually read.

Rescoped from class 3: None in this report. The domain dossier already carries the domain's one class-3 rescoping (device acceptability versus PFMT's own discontinuation record) under its reference-products section; this report's clinical-evidence scope did not surface a new class-3 question this pass.

Out of scope: Surgical SUI treatment, even though the guideline document cited [3] is titled around surgical scope and Statement 11 (non-surgical) sits inside it — only the non-surgical statement was read. 510(k) clearance detail, product codes and recalls for named devices; HCPCS/CPT coding and payer coverage policy; MAUDE complaint narratives (no connector reaches MAUDE anywhere in this repo); ICS consensus statements and NICE guidance (not queried this pass, per this report's declared scope).

Not searched vs. not found: A registered trial of closed-loop, EMG-gated electrical stimulation specifically for SUI was searched for directly this pass (trials connector, condition "stress urinary incontinence," intervention "closed loop stimulation") and not found — zero records, not an unsearched gap. Full text beyond the PubMed structured abstract was not searched for any of the nine sources above — methods, risk-of-bias detail, and funding disclosures for each review or trial were not read this pass, consistent with triaging at abstract depth before writing anything down. ICS consensus statements were not searched this pass, the same gap the domain dossier already records.

[inference] The two network meta-analyses [1][2] disagree on which single modality ranks best, which is consistent with a genuine difference in population (SUI-specific adult women vs. mixed-etiology incontinence in women 60+) and outcome metric (ICIQ-UI SF / leakage volume vs. cure/improvement odds) rather than with a real contradiction about any one device's efficacy — but this report cannot distinguish those explanations from the abstracts alone, and neither review's authors resolve it either [inference].

6. Claim Candidates